RxSight, Inc. last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $24.5 million (-19.1% year over year) and diluted EPS of -$0.39. It usually reports 6–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 6–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
25
-19.1%
|
-16
-65.3%
|
-0.39
-62.5%
|
|
Jul 6, 2026
6 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
27
-19.0%
|
-12
-2.6%
|
-0.29
+0.0%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
31
-18.5%
|
-16
-93.9%
|
-0.38
-90.0%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
33
-18.9%
|
-9
-54.1%
|
-0.22
-51.0%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
30
-14.1%
|
-10
-54.9%
|
-0.24
-50.0%
|
|
Jul 8, 2025
8 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
34
-3.6%
|
-12
-93.9%
|
-0.29
-81.2%
|
|
Apr 3, 2025
3 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
38
+28.4%
|
-8
+10.0%
|
-0.20
+20.0%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
40
+40.7%
|
-6
+35.3%
|
-0.15
+42.3%
|
Company profile
- Industry
- Ophthalmic Goods (SIC 3851)
- Listed as
- RXST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Aliso Viejo, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1111485
- Former names
- CALHOUN VISION INC (until Mar 20, 2014)
Other Ophthalmic Goods companies
- Alcon Inc ALC
- Cooper Companies, Inc. COO
- Bausch & Lomb Corp BLCO
- Warby Parker Inc. WRBY
- National Vision Holdings, Inc. EYE
- Staar Surgical Co STAA
- Innovative Eyewear Inc LUCY
Source: SEC EDGAR filings. This is company-reported data, not investment advice.